PMID- 2569032
OWN - NLM
STAT- MEDLINE
DCOM- 19890829
LR  - 20220330
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 7
IP  - 8
DP  - 1989 Aug
TI  - HER-2/neu oncogene protein and prognosis in breast cancer.
PG  - 1120-8
AB  - Amplification of the HER-2/neu oncogene was recently reported to predict poor 
      clinical outcome in node-positive breast cancer patients. Since expression of the 
      oncogene as its protein product might be even more closely related than gene 
      amplification to disease progression, we have now examined levels of the 
      HER-2/neu oncogene protein for its prognostic potential in both node-positive and 
      node-negative breast cancer. Using Western blot analysis, levels of this protein 
      were determined in 728 primary human breast tumor specimens. We examined 
      relationships between this protein and other established markers of prognosis, as 
      well as clinical outcome. In node-negative patients (n = 378), the HER-2/neu 
      protein failed to predict disease outcome. However, in node-positive patients (n 
      = 350), those patients with higher HER-2/neu protein had statistically shorter 
      disease-free (P = .0014) and overall survival (P less than .0001) than patients 
      with lower levels of the protein. Higher HER-2/neu protein was found in tumors 
      without estrogen receptor (ER) (P = .02) or progesterone receptor (PgR) (P = 
      .0003), and in patients with more than three positive lymph nodes (P = .04). A 
      significant correlation between levels of the HER-2/neu gene protein and 
      amplification of the gene itself was also found (n = 48, P less than .001). 
      Multivariate analyses in these patients showed that the HER-2/neu protein is a 
      significant independent predictor of both the disease-free and the overall 
      survival in node-positive breast cancer, even when other prognostic factors are 
      considered.
FAU - Tandon, A K
AU  - Tandon AK
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio, 
      78284-7884.
FAU - Clark, G M
AU  - Clark GM
FAU - Chamness, G C
AU  - Chamness GC
FAU - Ullrich, A
AU  - Ullrich A
FAU - McGuire, W L
AU  - McGuire WL
LA  - eng
GR  - CA 30195/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Oncogene Proteins, Viral)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antibody Specificity
MH  - Biomarkers, Tumor/*analysis
MH  - Blotting, Western
MH  - Breast Neoplasms/*analysis/genetics
MH  - Cell Line
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Oncogene Proteins, Viral/*analysis
MH  - Probability
MH  - Prognosis
MH  - Protein Kinases/*analysis
MH  - *Proto-Oncogenes
MH  - Receptor, ErbB-2
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
AID - 10.1200/JCO.1989.7.8.1120 [doi]
PST - ppublish
SO  - J Clin Oncol. 1989 Aug;7(8):1120-8. doi: 10.1200/JCO.1989.7.8.1120.